SOURCE: Tulip BioMed, Inc.

February 14, 2007 08:28 ET

Tulip BioMed Demonstrates Disposable Surgical Instruments at Recent Conferences

New Instruments Supporting Safer Cosmetic Surgery Well-Received by Surgeons

SAN DIEGO, CA -- (MARKET WIRE) -- February 14, 2007 --Tulip BioMed™, Inc. (PINKSHEETS: TPBD), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, comments on the exhibition of its new disposable cannulas for these markets at both the "New Horizons in Cosmetic Surgery" in Indian Wells (near Palm Springs), California, and "American Academy of Cosmetic Surgery - 23rd Annual Scientific Meeting" in Phoenix, Arizona.

Both conferences are designed for the experienced surgeon who is familiar with standard aesthetic procedures and wishes to learn more about newer, better technologies and techniques to enhance his or her practice. Tulip BioMed demonstrated its disposable, minimally-invasive micro-cannulas for fat harvest, transfer, re-injection and other surgical uses (already on the market) plus a series of five, versatile, disposable cannula models (proto-types) that work with standard aspiration machines as well as the syringe system (aesthetic) method of liposuction.

The Indian Wells conference featured J. William Little, MD, a well-known, Washington, DC-based aesthetic plastic surgeon who is a key specialist in fat transfer techniques. In a prior release Dr. Little stated, "Plastic surgery's recent emphasis on the reversal of mid-facial descent, combined with replacement -- rather than removal -- of lower eyelid fat, has made a difference in the quality of results." Dr. Little further commented, "Good surgeons are always looking for better and safer instrumentation. Tulip's blunt tip disposable cannulas will help us perform safer surgeries with more predictable results and are convenient for the O.R. staff."

The Phoenix conference featured Mark Berman, MD, and Robert Alexander, MD, DMD both well-known, aesthetic plastic surgeons who specialize in fat transfer techniques. Dr. Berman, through his presentations on both "Facial Fat Grafting" and "Lipo Augmentation," introduced Tulip BioMed instruments to the attending industry professionals. Tulip instruments were also used in Dr. Alexander's presentation on "Fat Transfer with Primary Liposuction." Dr. Alexander, a member of Tulip's Board of Scientific Advisors, is a strong proponent of the Tulip products as being superior in safety and quality.

The disposable instruments developed by Tulip BioMed are designed to solve cross-contamination issues by eliminating reuse of instruments in liposuction, fat transfer and other closed end cannula procedures. The lubricious coating is designed to not only decrease the trauma to the cells inside the lumen, but is also designed to increase the ease of manipulation for extraction and re-injection procedures, minimize bruising and shorten recovery periods.

Doctors and industry professionals who would like to discuss Tulip BioMed's advantage are encouraged to call the company at 800-978-8547.

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized Tulip brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information go to: Products are available for sale at

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

    Premier Funding Service
    Kelly Black
    Email Contact

    Heather Kerwin
    Investor Relations
    Email Contact

    (480) 649-8224 Office
    (480) 898-0406 Fax